Skip to main content

CareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference.

CareDx’s management is scheduled to present at the Raymond James & Associates’ 44th Annual Institutional Investors Conference on Monday, March 6th, 2023, at 4:35 PM ET. To listen to the webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  252.26
+2.35 (0.94%)
AAPL  273.05
+6.88 (2.58%)
AMD  296.67
+12.18 (4.28%)
BAC  53.19
-0.29 (-0.55%)
GOOG  335.53
+5.06 (1.53%)
META  675.25
+6.41 (0.96%)
MSFT  432.27
+8.11 (1.91%)
NVDA  201.36
+1.48 (0.74%)
ORCL  188.41
+7.25 (4.00%)
TSLA  391.41
+4.99 (1.29%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.